Is Tempest Therapeutics Stock a Good Investment?
Tempest Therapeutics Investment Advice | TPST |
- Examine Tempest Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Tempest Therapeutics' leadership team and their track record. Good management can help Tempest Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Tempest Therapeutics' business and its evolving consumer preferences.
- Compare Tempest Therapeutics' performance and market position to its competitors. Analyze how Tempest Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Tempest Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Tempest Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Tempest Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Tempest Therapeutics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Relatively risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Tempest Therapeutics Stock
Researching Tempest Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 23.0% of the company shares are owned by institutional investors. The book value of Tempest Therapeutics was at this time reported as 1.21. The company recorded a loss per share of 1.58. Tempest Therapeutics last dividend was issued on the 10th of December 2018. The entity had 1:15 split on the 28th of June 2021.
To determine if Tempest Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Tempest Therapeutics' research are outlined below:
| Tempest Therapeutics generated a negative expected return over the last 90 days | |
| Tempest Therapeutics has some characteristics of a very speculative penny stock | |
| Tempest Therapeutics has high historical volatility and very poor performance | |
| Tempest Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (29.49 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Tempest Therapeutics currently holds about 51.62 M in cash with (27.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.95, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Tempest Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma |
Tempest Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Tempest Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Tempest Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Tempest Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Tempest Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-06 | 2024-09-30 | -0.36 | -0.41 | -0.05 | 13 | ||
2023-11-08 | 2023-09-30 | -0.57 | -0.48 | 0.09 | 15 | ||
2023-05-10 | 2023-03-31 | -0.64 | -0.55 | 0.09 | 14 | ||
2023-03-22 | 2022-12-31 | -0.76 | -0.63 | 0.13 | 17 | ||
2022-08-15 | 2022-06-30 | -0.92 | -0.79 | 0.13 | 14 | ||
2022-11-08 | 2022-09-30 | -0.8 | -0.66 | 0.14 | 17 | ||
2021-11-10 | 2021-09-30 | -1.05 | -1.21 | -0.16 | 15 | ||
2021-03-29 | 2020-12-31 | -5.15 | -5.85 | -0.7 | 13 |
Know Tempest Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Tempest Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Tempest Therapeutics backward and forwards among themselves. Tempest Therapeutics' institutional investor refers to the entity that pools money to purchase Tempest Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Susquehanna International Group, Llp | 2024-09-30 | 45.3 K | Bank Of America Corp | 2024-09-30 | 43.2 K | State Street Corp | 2024-09-30 | 41.5 K | Empower Advisory Group Llc | 2024-09-30 | 35 K | Tocqueville Asset Management L.p. | 2024-09-30 | 32.8 K | Advisor Group Holdings, Inc. | 2024-09-30 | 25.4 K | Boothbay Fund Management, Llc | 2024-09-30 | 24.6 K | Xtx Topco Ltd | 2024-09-30 | 24 K | Two Sigma Investments Llc | 2024-09-30 | 22.9 K | Blackrock Inc | 2024-09-30 | 551.6 K | Altium Capital Management, Lp | 2024-09-30 | 545 K |
Tempest Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 40.4 M.Market Cap |
|
Tempest Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.66) | (0.69) | |
| Return On Capital Employed | (0.79) | (0.83) | |
| Return On Assets | (0.66) | (0.69) | |
| Return On Equity | (1.27) | (1.33) |
Determining Tempest Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Tempest Therapeutics is a good buy. For example, gross profit margin measures Tempest Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Tempest Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Tempest Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Tempest Therapeutics. Check Tempest Therapeutics' Beneish M Score to see the likelihood of Tempest Therapeutics' management manipulating its earnings.
Evaluate Tempest Therapeutics' management efficiency
Tempest Therapeutics has return on total asset (ROA) of (0.5428) % which means that it has lost $0.5428 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.8926) %, meaning that it created substantial loss on money invested by shareholders. Tempest Therapeutics' management efficiency ratios could be used to measure how well Tempest Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.69 in 2025. Return On Capital Employed is likely to drop to -0.83 in 2025. Liabilities And Stockholders Equity is likely to gain to about 70.9 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 9.6 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.00 | 1.90 | |
| Tangible Book Value Per Share | 2.00 | 1.90 | |
| Enterprise Value Over EBITDA | (1.54) | (1.62) | |
| Price Book Value Ratio | 2.91 | 3.14 | |
| Enterprise Value Multiple | (1.54) | (1.62) | |
| Price Fair Value | 2.91 | 3.14 | |
| Enterprise Value | 56.7 M | 44.6 M |
Leadership at Tempest Therapeutics emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.
Beta (2.78) |
Basic technical analysis of Tempest Stock
As of the 18th of January 2025, Tempest Therapeutics has the Risk Adjusted Performance of (0.01), variance of 23.9, and Coefficient Of Variation of (5,103). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Tempest Therapeutics, as well as the relationship between them.Tempest Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tempest Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tempest Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Tempest Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Tempest Therapeutics' Outstanding Corporate Bonds
Tempest Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Tempest Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Tempest bonds can be classified according to their maturity, which is the date when Tempest Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| TELUS P 37 Corp BondUS87971MBF95 | View | |
| TELUS P 46 Corp BondUS87971MBH51 | View | |
| TELUS P 28 Corp BondUS87971MBD48 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| TCN 34 13 MAY 32 Corp BondUS87971MBW29 | View | |
| International Game Technology Corp BondUS460599AD57 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Tempest Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Tempest Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.01) | |||
| Market Risk Adjusted Performance | (0.04) | |||
| Mean Deviation | 3.32 | |||
| Coefficient Of Variation | (5,103) | |||
| Standard Deviation | 4.89 | |||
| Variance | 23.9 | |||
| Information Ratio | (0.03) | |||
| Jensen Alpha | (0.15) | |||
| Total Risk Alpha | (0.22) | |||
| Treynor Ratio | (0.05) | |||
| Maximum Drawdown | 24.26 | |||
| Value At Risk | (8.42) | |||
| Potential Upside | 6.38 | |||
| Skewness | 0.5766 | |||
| Kurtosis | 4.04 |
| Risk Adjusted Performance | (0.01) | |||
| Market Risk Adjusted Performance | (0.04) | |||
| Mean Deviation | 3.32 | |||
| Coefficient Of Variation | (5,103) | |||
| Standard Deviation | 4.89 | |||
| Variance | 23.9 | |||
| Information Ratio | (0.03) | |||
| Jensen Alpha | (0.15) | |||
| Total Risk Alpha | (0.22) | |||
| Treynor Ratio | (0.05) | |||
| Maximum Drawdown | 24.26 | |||
| Value At Risk | (8.42) | |||
| Potential Upside | 6.38 | |||
| Skewness | 0.5766 | |||
| Kurtosis | 4.04 |
Consider Tempest Therapeutics' intraday indicators
Tempest Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Tempest Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Tempest Therapeutics time-series forecasting models is one of many Tempest Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Tempest Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Tempest Stock media impact
Far too much social signal, news, headlines, and media speculation about Tempest Therapeutics that are available to investors today. That information is available publicly through Tempest media outlets and privately through word of mouth or via Tempest internal channels. However, regardless of the origin, that massive amount of Tempest data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Tempest Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Tempest Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Tempest Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Tempest Therapeutics alpha.
Tempest Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Tempest Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Tempest Therapeutics Corporate Management
| Nicholas Maestas | VP Secretary | Profile | |
| Dr Dubensky | Pres Director | Profile | |
| Justin Trojanowski | Treasurer Controller | Profile | |
| RAC Sakai | Head Quality | Profile | |
| Samuel MD | Executive Officer | Profile | |
| Petpiboon Prasit | Acting Director | Profile | |
| Anne Moon | Project Leadership | Profile |
Additional Tools for Tempest Stock Analysis
When running Tempest Therapeutics' price analysis, check to measure Tempest Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tempest Therapeutics is operating at the current time. Most of Tempest Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tempest Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tempest Therapeutics' price. Additionally, you may evaluate how the addition of Tempest Therapeutics to your portfolios can decrease your overall portfolio volatility.